Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
How Drug Discovery Is Tackling Global Health Challenges
In this DDW podcast episode, host Bruno Quinney discusses two recent DDW articles: one on the urgent need to combat antimicrobial resistance (AMR) with insights from Professor Janet Hemingway, and another on the rapid expansion of mRNA therapeutics. Hemingway highlights the growing pipeline of novel antibiotics and vaccines, the challenges SMEs face in clinical development, and the need for stronger incentives to re‑engage big pharma. The mRNA segment outlines how the technology, propelled by COVID‑19 vaccine success, has surged from a $3.4 billion market in 2018 to roughly $40 billion today, with emerging applications in vaccines, cancer, and protein replacement therapies. Both topics underscore how innovative drug discovery is addressing global health threats while confronting funding and regulatory hurdles.
Pa. Air Medical Pilot Reaches 3,000 Patient Transports Milestone
Mike Moore, JeffSTAT lead pilot for Air Methods, completed his 3,000th patient transport in March, a milestone reached by few air‑medical pilots. The achievement caps an 18‑year tenure at the Lansdale base and reflects over 7,750 total flight hours, including...
Anti‑vaxxer Leads Healthcare: Real April Fool’s Situation
Who needs April Fools' when we have an anti-vaxxer running our healthcare and public health.
Mental Health Care Isn’t Free Speech; Conversion Therapy Is Abuse
The words of a MH provider, when they are providing care, are not and should never be considered free speech. All of us should be held accountable to do no harm. In the words of Justice Ketanji Brown Jackson: “Like it or...
GSK Reports the NMPA Approval of Exdensur (Depemokimab) for Severe Asthma
GlaxoSmithKline’s biologic Exdensur (depemokimab) received approval from China’s National Medical Products Administration as an add‑on maintenance therapy for patients aged 12 and older with severe eosinophilic asthma. The approval is based on Phase III SWIFT‑1 (382 participants) and SWIFT‑2 (380 participants)...
Advocating Bills to Expand Right‑to‑Try for Severe Illnesses
Today @theA4LI is at the New Hampshire State House supporting HB 1734 and HB 1735, two bills that would license experimental treatment centers and expand Right to Try protections to patients with severe illness, not just terminal conditions. As a longevity...
What’s New in Thermoplastic Polyurethanes How ChronoFlex™ S Delivers Softness and Strength for Implantable Medical Devices
Mitsubishi Chemical Group has launched ChronoFlex S, a 60A thermoplastic polyurethane that delivers silicone‑like softness while retaining the superior tensile strength and abrasion resistance of TPU. The material contains 36% USDA‑certified biobased content and can be processed by melt, extrusion, injection...
Trim Visceral Fat to Neutralize High Lp(a) Risk
Lp(a) is the new Voldemort of cardiology—a genetically determined risk factor that can raise your risk of heart disease by >200%. And while elevated Lp(a) is largely written into your DNA, there’s good news: You may be able to neutralize its...
$14K Grant Boosts Heart Health Checks for Mass. Firefighters
Amesbury’s City Council approved a $14,858 grant from the Massachusetts Interlocal Insurance Association to fund cardiac screenings for 17 of the fire department’s 39 members. The grant, secured by Lieutenant David Carpentier, will cover expensive heart‑health evaluations scheduled for late...
The Biotech Bi-Weekly: Cell Barcoding, Compound Optimization and the Trillion Cell Atlas
The biotech sector is witnessing a wave of collaborations and product launches aimed at accelerating drug discovery and expanding genomic knowledge. Biotium introduced the ViaPlex™ 2‑Color Cell Barcoding Kit, enabling multiplex analysis of up to 15 cell populations in a...
Oric to Advance Prostate Cancer Drug to Phase 3, but Combo Choice Raises Doubts
Oric Pharmaceuticals announced that its PRC2 inhibitor will move into a registrational Phase 3 trial for prostate cancer after reporting encouraging safety and disease‑control signals in a Phase 1b study. The company plans to evaluate the drug both as a...
Health Care Funding: Information on Crisis Pregnancy Centers, Fiscal Years 2018 Through 2024
The Government Accountability Office identified that the Department of Health and Human Services obligated at least $34 million in federal grants to 16 crisis pregnancy centers (CPCs) between fiscal years 2018 and 2024. CPCs, typically nonprofit and faith‑based, offer free or...
Smart IUD Could ‘Provide Insights We’ve Never Had Before’
Verso Biosense, based in Oxfordshire, is creating a wireless smart IUD that continuously records uterine temperature and oxygen levels. The device aims to generate real‑time data to help clinicians understand why some IVF cycles fail and to identify conditions that...
Physicians Must Drive AI Design in Healthcare
Why physicians must lead the design of artificial intelligence in health care [PODCAST] http://dlvr.it/TRprTk Policy #HealthIT
AHA's 2026 Guidelines Push Plant‑Based Protein, Redefine Heart‑Healthy Diet
The American Heart Association released its 2026 scientific statement, shifting its heart‑healthy recommendations toward plant‑based protein and tighter limits on saturated fat. The guidance, aimed at the entire U.S. population, frames nine evidence‑based dietary features to curb cardiovascular disease.
Frontier Medicines Grants Ex-China Rights of FMC-220 to LG Chem
Frontier Medicines has granted LG Chem an exclusive global license to develop and commercialize its covalent p53 Y220C activator FMC-220 outside Greater China, while retaining full rights within that region. LG Chem will manage regulatory filings, global clinical development, and...
MyGevity Unveils DNA‑Linked Real‑Time Lab Platform for At‑Home Longevity Testing
MyGevity announced the nationwide launch of a precision‑health platform that links at‑home genetic testing to real‑time lab diagnostics through Quest Diagnostics. The service combines DNA analysis, epigenetic age scoring and continuous biomarker monitoring, delivering personalized recommendations and a dedicated genomics...
FDA Grants Accelerated Approval to Denali's Avlayah, First New Hunter Syndrome Therapy in 20 Years
The U.S. Food and Drug Administration granted accelerated approval to Denali Therapeutics' intravenous enzyme replacement therapy Avlayah, marking the first new treatment for Hunter syndrome in two decades. The approval could extend lives and curb cognitive decline for the roughly...
Rhythm Pharmaceuticals Stock Jumps 12.6% After FDA Expands Imcivree Label
Rhythm Pharmaceuticals saw its shares rise 12.58% after the FDA approved Imcivree for acquired hypothalamic obesity, expanding the drug’s addressable U.S. market by 10,000 patients. The move follows a 46% revenue jump to $189.8 million in 2025 but comes amid recent...
Hugel Taps Hans Biomed to Sell CellREDM Injectable, Expanding B2B Aesthetic Portfolio
Hugel Inc. signed a distribution deal with Hans Biomed to sell the ECM‑based injectable CellREDM™ in South Korea, marking the company's first partnership on a third‑party product and a push to broaden its B2B aesthetic offerings.
New Analysis Says GLP-1s Will Reverse Climate Change
A new analysis in the Journal of Global Metabolic Systems proposes that widespread use of GLP‑1 weight‑loss drugs could help reverse climate change. By reducing overall caloric demand, the model predicts lower livestock production, especially beef and dairy, leading to...
WHO Expands TB Diagnostic Toolkit with Point-of-Care Tests, Tongue Swabs, and Sample Pooling
The World Health Organization released new guidelines that introduce near point‑of‑care nucleic acid amplification tests, tongue‑swab specimens, and sputum pooling to speed and broaden TB diagnosis. These tools aim to shift testing to primary‑care settings, lower costs, and improve throughput...
Autistic People Are More Likely to Experience Suicidal Crisis. 988 Is Changing to Serve Them Better
The 988 Lifeline, the nation’s 24‑hour free suicide‑prevention service, has fielded roughly 25 million contacts since its launch in July 2022. Autistic individuals, who are significantly more likely to experience suicidal thoughts, often encounter communication barriers that can turn a crisis call...
Fitbit AI Coach Gains Access to Medical Records
Google is making Fitbit meaningfully more connected to medical data. Its AI coach will be able to take into account not just wearable signals, but also linked medical records — labs, medications, and visit history: https://blog.google/products-and-platforms/devices/fitbit/fitbit-personal-health-coach-updates-2026/ And this is where the story gets...
Can This Antioxidant Support Ovarian Cancer Treatment? What Research Shows
Researchers reviewed pre‑clinical studies and performed molecular‑docking simulations to assess resveratrol’s interaction with ovarian cancer proteins. The analysis suggests the antioxidant may modulate cell growth, inflammation, hormone signaling, and stress pathways, potentially enhancing the efficacy of chemotherapy and radiation. While...
Patients Know Best and Heartfelt Technologies Collaborate to Accelerate Clinical Trial Recruitment
Patients Know Best teamed with Heartfelt Technologies to automate recruitment for the Innovate UK‑funded HF‑TRACK trial, enrolling 16 participants in just four weeks—a 135% increase over the trial’s average rate. The partnership leveraged PKB’s coded health‑record data to display a...
Reimagining High-Acuity Care: The Role of AI in Neurological Patient Pathways
High‑acuity neurological care is grappling with massive data streams and fragmented handoffs, prompting a push for AI‑driven decision support and unified digital pathways. Machine‑learning models now analyze multimodal ICU inputs to flag early deterioration and streamline imaging interpretation. Yet the...
AI Could Help NHS Clinicians Diagnose Childhood Sleep Apnoea, Study Finds
Seluna’s AI‑driven autoscoring software accurately identified paediatric sleep apnoea in a 500‑patient NHS trial, achieving 100 % sensitivity for severe cases and processing each study in under five minutes. The platform matched human inter‑scorer variability while dramatically cutting analysis time from...
Here Is Why Ocular Therapeutix (OCUL) Is Highly Favored by Hedge Funds
Ocular Therapeutix (OCUL) received upgraded price targets from Bank of America and Clear Street, raising them to $27 and $28 respectively while maintaining Buy ratings. Both firms highlighted the Phase 3 SOL‑1 trial, which demonstrated durable control of wet age‑related macular...
Wearable AI Devices Market Insights Report 2026-2036 Featuring Strategic Analysis of Apple, Samsung Electronics, Google, Huawei Technologies Co., Sony Corp....
The global wearable AI devices market is projected to surge from $69.8 billion in 2026 to about $270.2 billion by 2036, delivering a 14.5% compound annual growth rate. Smartwatches dominate the market today, while eye‑wear is set to post the fastest growth...
Productivity Enhancing Bioreactor for Scalable Organoid Culture
AMSBIO introduced RPMotion, a spinning organoid bioreactor that accelerates and automates 3‑D cell culture for drug discovery, disease modeling and regenerative medicine. The system delivers up to five‑fold faster organoid expansion while cutting reagent costs by roughly 60% and labor...
Yes, GLP-1s Are Changing What Food People Buy — Here's How
GLP‑1 drugs such as Ozempic and Wegovy are prompting measurable changes in grocery purchasing patterns. A Danish study of 1,177 adults, covering nearly two million transactions, found that users bought foods with slightly lower calories, sugar, carbohydrates and saturated fat,...
ACC 2026: Sotatercept Shows Signal in CpcPH-HFpEF at Lower Dose
At the 2026 ACC Scientific Session, the phase‑II CADENCE trial showed that sotatercept (WINREVAIR) reduced pulmonary vascular resistance in adults with combined post‑ and precapillary pulmonary hypertension linked to HFpEF (CpcPH‑HFpEF). The study randomized 164 patients, median age 75, to...
Development And Validation Of Prognostic Scale In Respiratory Condition for Physiotherapist in ICU
Researchers have designed and validated a prognostic scale tailored for physiotherapists treating respiratory conditions in intensive care units. The scale achieved a content validity ratio of 0.846, indicating strong reliability, while Cohen’s kappa testing demonstrated perfect inter‑rater agreement (p < 0.05). Validation...
Corewell Health’s Jarve Says Population Health Data Challenges Demand Internal Builds
In this episode, Dr. Bob Jarvie, Associate CMIO and Medical Director for Population Health Analytics at Corewell Health, explains why the health system built its own internal population health data platform instead of relying on external vendors. He highlights the...
Treating Arthritis of the Hands
Arthritis of the hands, wrists and fingers—most commonly osteoarthritis, rheumatoid arthritis, or post‑traumatic arthritis—affects millions and can severely limit daily function. Dr. Kevin Chung of the University of Michigan Health explains that early diagnosis through imaging or labs enables a...
Developing Patient-Reported Outcome Measures of Timely Experience of Diagnosis (PROMOTE-Dx) for Cancer
The research team released PROMOTE‑Dx, a validated patient‑reported outcome measure that captures the timeliness of cancer diagnosis. The instrument was created through extensive survey development, cognitive testing, and psychometric validation. PROMOTE‑Dx is designed for health‑care systems and insurers to monitor...
Trump’s One Big Beautiful Bill Act Darkens Outlook for Government-Backed Clinics
Nebraska will become the first state to implement the work‑requirement provisions of President Trump’s One Big Beautiful Bill Act, forcing certain Medicaid expansion enrollees to prove 80 hours of work or volunteer each month. Bluestem Health, a safety‑net clinic in Lincoln serving 21,000...
Quality Care Collaboratives for Maternal Health Across U.S. States
A new scoping review will map how state‑based maternal and perinatal quality collaboratives (M/PQCs) implement safety toolkits and bundles across U.S. health systems. The review will include studies published after 2000, drawing from MEDLINE, Embase, CINAHL, the Maternity and Infant...
A Longitudinal Multi‑proxy Geospatial Classification of Peri‑urban Transitions Across Community Health Units in Coastal Kenya
The study applied five publicly available geospatial proxies to classify settlement dynamics across ten Community Health Units in coastal Kenya from 2017 to 2024. Median cumulative changes were 62% for nighttime lights, 111% for Sentinel‑2 built‑up, 34% for WorldPop built‑up,...
MediBeacon Secures CE Mark Certification for TGFR Monitor and Sensor
MediBeacon announced that its transdermal glomerular filtration rate (TGFR) monitor and reusable sensor have earned CE Mark certification under the EU Medical Device Regulation. The Class IIa devices, part of the broader TGFR system that includes the Lumitrace injection and disposable...
Decode AI Health Jargon with Our Survival Guide
Navigating AI in medicine and digital health can feel like ordering a coffee at that new hipster café downtown. Here is our survival guide in the bewildering world of digital health terminology. We’re decoding the lingo, from radiomics and theranostics to...
Paragon Launches Korsana Biosciences, Targeting Alzheimer's
Paragon launched its 7th company today -- Korsana Biosciences, merging into the $CYCN public shell. New ticker will be $KRSA. Lead drug candidate is a shuttled anti-amyloid beta antibody for Alzheimer's disease in early studies. https://t.co/RcJ8adMakm
Symeres and Ambagon Collaborate for Colorectal Cancer Molecules
Symeres has partnered with Ambagon Therapeutics to evaluate molecular‑glue compounds for colorectal cancer. The collaboration will leverage Symeres’ in‑vitro assays, surface‑plasmon resonance kinetics, and fluorescence microscopy to characterize ternary‑complex formation and downstream pathway effects. Symeres will also profile each candidate...
Symeres and Ambagon Collaborate for Colorectal Cancer Molecules
Symeres has partnered with Ambagon Therapeutics to evaluate Ambagon’s molecular glue candidates for colorectal cancer. The collaboration will use Symeres’ in‑vitro assays, surface plasmon resonance, fluorescence microscopy and a 102‑cell line panel to characterize ternary complex kinetics and downstream pathway...
Boston Scientific Receives FDA Clearance for the Asurys Fluid Management System
Boston Scientific announced FDA 510(k) clearance for its Asurys Fluid Management System, a device that provides automated irrigation and intrarenal pressure control during endoscopic urologic procedures such as ureteroscopy. The system integrates with the LithoVue Elite single‑use digital ureteroscope, allowing...
STAT+: The Biotech Scorecard for the Second Quarter: 23 Stock-Moving Events to Watch
STAT’s quarterly biotech scorecard lists 23 upcoming events that could move biotech stocks in Q2 2026. Highlights include Phase 3 results from Abivax’s obefazimod in ulcerative colitis and Allogene Therapeutics’ interim data on its cema‑cel CAR‑T therapy for B‑cell lymphoma. The...
Lilly Moves Deeper Into Sleep Medicine with up to $7.8 Billion Centessa Deal
Eli Lilly announced a definitive agreement to acquire UK‑based Centessa Pharmaceuticals for up to $7.8 billion, paying $38 per share in cash and up to $9 per share in contingent milestones. The acquisition gives Lilly control of Centessa’s orexin‑receptor‑2 agonist pipeline,...
‘We’re Failing Newborns’: The Global Push to Reduce Infant Deaths Is Losing Steam
The United Nations’ 2030 goal to cut neonatal mortality to 12 per 1,000 live births is slipping, with more than 60 countries—especially in Africa—far off track. Neonatal deaths remain at 2.3 million annually, driven by prematurity, asphyxia, and infections, while power...
Anavex Updates Regulatory Strategy for Blarcamesine
Anavex Life Sciences has withdrawn its European Union marketing authorization application for blarcamesine and will collect additional data while maintaining dialogue with the European Medicines Agency. The company has concurrently submitted new data to the U.S. FDA to explore a...